Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Original Article
L.J. Costa, N.J. Bahlis, A. Perrot, A.K. Nooka, J. Lu, C. Pawlyn, R. Mina, G. Caeiro, A. Kentos, V. Hungria, D. Reece, T. Niu, A.K. Mylin, C.T. Hansen, R. Teipel, B. Besemer, M.A. Dimopoulos, E. Zamagni, S. Yoshihara, K. Kim, C.K. Min, P. Geerts, E.V. Leeuwen-Segarceanu, A. Tyczynska, J.L. Reguera, M. Johansson, M. Hansson, M. Turgut, M. Grey, S. Sidana, P. Rodriguez-Otero, J. Martinez-Lopez, H. Hashmi, R. Carson, R. Kobos, W. Sun, K. Lantz, A. Seifert, D. Briseno-Toomey, L. O’Rourke, M. Rubin, D. Vieyra, L. Kang, and M.V. Mateos
N Engl J Med 2026;394:739-752
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Please sign in or create an account to take the course.

Facebook
X
LinkedIn
Forward